Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9
Grégoire Cullot, Julian Boutin, Sabrina Fayet, Florence Prat, Juliette Rosier, David Cappellen, Isabelle Lamrissi, Perrine Pennamen, Julie Bouron, Samuel Amintas, Chloé Thibault, Isabelle Moranvillier, Elodie Laharanne, Jean‐Philippe Merlio, Veronique Guyonnet‐Dupérat, Jean‐Marc Blouin, Emmanuel Richard, Sandrine Dabernat, François Moreau‐Gaudry, Aurélie Bedel
Abstract
The CRISPR-Cas9 system has revolutionized our ability to precisely modify the genome and has led to gene editing in clinical applications. Comprehensive analysis of gene editing products at the targeted cut-site has revealed a complex spectrum of outcomes. ON-target genotoxicity is underestimated with standard PCR-based methods and necessitates appropriate and more sensitive detection methods. Here, we present two complementary Fluorescence-Assisted Megabase-scale Rearrangements Detection (FAMReD) systems that enable the detection, quantification, and cell sorting of edited cells with megabase-scale loss of heterozygosity (LOH). These tools reveal rare complex chromosomal rearrangements caused by Cas9-nuclease and show that LOH frequency depends on cell division rate during editing and p53 status. Cell cycle arrest during editing suppresses the occurrence of LOH without compromising editing. These data are confirmed in human stem/progenitor cells, suggesting that clinical trials should consider p53 status and cell proliferation rate during editing to limit this risk by designing safer protocols.